OBJECTIVE: Rheumatoid arthritis is associated with an excess of agalactosylated (G0) IgG that is considered relatively proinflammatory. Assessment of this association in juvenile idiopathic arthritis (JIA) is complicated by age-dependent IgG glycan variation. The aim of this study was to conduct the first large-scale survey of IgG glycans in healthy children and patients with JIA, with a focus on early childhood, the time of peak JIA incidence. METHODS: IgG glycans from healthy children and disease-modifying antirheumatic drug-naive patients with JIA were characterized using high-performance liquid chromatography. Agalactosylated glycans were quantitated with reference to monogalactosylated (G1) species. Associations were sought between the G0:G1 ratio and disease characteristics. RESULTS: Among healthy children ages 9 months to 16 years (n = 165), the G0:G1 ratio was highly age dependent, with the ratio peaking to 1.19 in children younger than age 3 years and declining to a nadir of 0.83 after age 10 years (Spearman's ρ = 0.60, P < 0.0001). In patients with JIA (n = 141), the G0:G1 ratio was elevated compared with that in control subjects (1.32 versus 1.02; P < 0.0001). The G0:G1 ratio corrected for age was abnormally high in all JIA subtypes (enthesitis-related arthritis was not assessed), most strikingly in systemic JIA. Glycosylation aberrancy was comparable in patients with and those without antinuclear antibodies and in both early- and late-onset disease and exhibited at most a weak correlation with markers of inflammation. CONCLUSION: IgG glycosylation is skewed toward proinflammatory G0 variants in healthy children, in particular during the first few years of life. This deviation is exaggerated in patients with JIA. The role for IgG glycan variation in immune function in children, including the predilection of JIA for early childhood, remains to be defined.
OBJECTIVE:Rheumatoid arthritis is associated with an excess of agalactosylated (G0) IgG that is considered relatively proinflammatory. Assessment of this association in juvenile idiopathic arthritis (JIA) is complicated by age-dependent IgGglycan variation. The aim of this study was to conduct the first large-scale survey of IgGglycans in healthy children and patients with JIA, with a focus on early childhood, the time of peak JIA incidence. METHODS:IgGglycans from healthy children and disease-modifying antirheumatic drug-naive patients with JIA were characterized using high-performance liquid chromatography. Agalactosylated glycans were quantitated with reference to monogalactosylated (G1) species. Associations were sought between the G0:G1 ratio and disease characteristics. RESULTS: Among healthy children ages 9 months to 16 years (n = 165), the G0:G1 ratio was highly age dependent, with the ratio peaking to 1.19 in children younger than age 3 years and declining to a nadir of 0.83 after age 10 years (Spearman's ρ = 0.60, P < 0.0001). In patients with JIA (n = 141), the G0:G1 ratio was elevated compared with that in control subjects (1.32 versus 1.02; P < 0.0001). The G0:G1 ratio corrected for age was abnormally high in all JIA subtypes (enthesitis-related arthritis was not assessed), most strikingly in systemic JIA. Glycosylation aberrancy was comparable in patients with and those without antinuclear antibodies and in both early- and late-onset disease and exhibited at most a weak correlation with markers of inflammation. CONCLUSION:IgG glycosylation is skewed toward proinflammatory G0 variants in healthy children, in particular during the first few years of life. This deviation is exaggerated in patients with JIA. The role for IgGglycan variation in immune function in children, including the predilection of JIA for early childhood, remains to be defined.
Authors: Ross E Petty; Taunton R Southwood; Prudence Manners; John Baum; David N Glass; Jose Goldenberg; Xiaohu He; Jose Maldonado-Cocco; Javier Orozco-Alcala; Anne-Marie Prieur; Maria E Suarez-Almazor; Patricia Woo Journal: J Rheumatol Date: 2004-02 Impact factor: 4.666
Authors: Jun Wang; Crina I A Balog; Kathrin Stavenhagen; Carolien A M Koeleman; Hans Ulrich Scherer; Maurice H J Selman; André M Deelder; Tom W J Huizinga; René E M Toes; Manfred Wuhrer Journal: Mol Cell Proteomics Date: 2011-03-03 Impact factor: 5.911
Authors: Michael G Barnes; Alexei A Grom; Susan D Thompson; Thomas A Griffin; Lorie K Luyrink; Robert A Colbert; David N Glass Journal: Arthritis Rheum Date: 2010-11
Authors: Emma M Ogilvie; Mark S Fife; Susan D Thompson; Natalie Twine; Monica Tsoras; Marta Moroldo; Sheila A Fisher; Cathryn M Lewis; Anne-Marie Prieur; David N Glass; Patricia Woo Journal: Arthritis Rheum Date: 2003-11
Authors: Altan Ercan; Jing Cui; Melissa M Hazen; Franak Batliwalla; Louise Royle; Pauline M Rudd; Jonathan S Coblyn; Nancy Shadick; Michael E Weinblatt; Peter Gregersen; David M Lee; Peter A Nigrovic Journal: Arthritis Res Ther Date: 2012-03-05 Impact factor: 5.156
Authors: Margaret E Ackerman; Max Crispin; Xiaojie Yu; Kavitha Baruah; Austin W Boesch; David J Harvey; Anne-Sophie Dugast; Erin L Heizen; Altan Ercan; Ickwon Choi; Hendrik Streeck; Peter A Nigrovic; Chris Bailey-Kellogg; Chris Scanlan; Galit Alter Journal: J Clin Invest Date: 2013-04-08 Impact factor: 14.808
Authors: Altan Ercan; Wendy M Kohrt; Jing Cui; Kevin D Deane; Marija Pezer; Elaine W Yu; Jonathan S Hausmann; Harry Campbell; Ursula B Kaiser; Pauline M Rudd; Gordan Lauc; James F Wilson; Joel S Finkelstein; Peter A Nigrovic Journal: JCI Insight Date: 2017-02-23
Authors: Hao D Cheng; Henning Stöckmann; Barbara Adamczyk; Ciara A McManus; Altan Ercan; Ingrid A Holm; Pauline M Rudd; Margaret E Ackerman; Peter A Nigrovic Journal: Glycobiology Date: 2017-12-01 Impact factor: 4.313
Authors: Hao D Cheng; Irit Tirosh; Noortje de Haan; Henning Stöckmann; Barbara Adamczyk; Ciara A McManus; Róisín O'Flaherty; Gordon Greville; Radka Saldova; Francisco A Bonilla; Luigi D Notarangelo; Gertjan J Driessen; Ingrid A Holm; Pauline M Rudd; Manfred Wuhrer; Margaret E Ackerman; Peter A Nigrovic Journal: J Allergy Clin Immunol Date: 2019-10-24 Impact factor: 10.793
Authors: Xing Zhou; Francesca Motta; Carlo Selmi; William M Ridgway; M Eric Gershwin; Weici Zhang Journal: Autoimmun Rev Date: 2021-03-14 Impact factor: 9.754
Authors: Andrew Dauber; Altan Ercan; Jack Lee; Philip James; Pieter P Jacobs; David J Ashline; Sophie R Wang; Timothy Miller; Joel N Hirschhorn; Peter A Nigrovic; Robert Sackstein Journal: Hum Mol Genet Date: 2014-01-08 Impact factor: 5.121
Authors: Gerhild Zauner; Maurice H J Selman; Albert Bondt; Yoann Rombouts; Dennis Blank; André M Deelder; Manfred Wuhrer Journal: Mol Cell Proteomics Date: 2013-01-16 Impact factor: 5.911